Integrative analysis identifies FBXO5 as a critical mediator of CRPC progression and bone metastatic potential.

Journal: Discover oncology
Published Date: Aug 7, 2025

Abstract

INTRODUCTION: Castration-resistant prostate cancer (CRPC) poses a major clinical challenge due to its aggressive nature, therapeutic resistance, and frequent progression to bone metastasis. Emerging evidence suggests that E3 ubiquitin ligases play a key role in cancer progression, yet their involvement in CRPC remains poorly understood.

Authors

  • Rajnikant Raut
    Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, 502285, India.
  • Devesh Srivastava
    Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University (Formerly DCE), Shahbad Daulatpur, Bawana Road, Delhi, 110042, India.
  • Amit Kumar Chakraborty
    Department of Translational Dental Medicine, Boston University Henry M. Goldman School of Dental Medicine, 700 Albany Street, Boston, MA, 02118, USA.
  • Manish V Bais
    Department of Translational Dental Medicine, Boston University Henry M. Goldman School of Dental Medicine, 700 Albany Street, Boston, MA, 02118, USA.
  • Parul Mishra
    Department of Animal Biology, School of Life Sciences, University of Hyderabad, Hyderabad, 500046, India.
  • Ashish Misra
    Department of Biotechnology, Indian Institute of Technology Hyderabad, Kandi, Sangareddy, 502285, India. ashishmisra@bt.iith.ac.in.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals